Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, announced the launch of Dehydrated Alcohol Injection, USP in the United States as a therapeutic...

Cronus Pharma LLC, a fully integrated research, development, manufacturing, sales and marketing animal health pharmaceutical company, announces the launch of Butorphic® (Butorphanol Tartrate) Sterile...

Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), and Sentinel BioTherapeutics, a clinical-stage biotechnology company advancing...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma")  announced LEQSELVI™...

TrueMed, a global leader in AI-based counterfeit detection, announced a strategic collaboration with Alliance Pharmaceuticals Ltd, a U.S.-based pharmaceutical solutions provider, to proactively...

Jiangsu Hengrui Pharmaceuticals Co., Ltd. a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first-...

Duality Biotherapeutics' partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology therapies,  announced the first patient has been dosed in...

Novogene Europe announces the installation of its fifth Illumina NovaSeq X Plus sequencing system, expanding high-throughput sequencing capacity to meet surging European demand. This strategic...

The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells...

Aurobindo Pharma has received marketing authorisation for its cancer treatment medication Dazublys. In an exchange filing, the company said that CuraTeQ Biologics, a wholly owned subsidiary of the...

Fresenius announced that its operating company Fresenius Kabi, has introduced two new biosimilars - Conexxence® (denosumab-bnht) and Bomyntra® (denosumab-bnht) - in the United States.

A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be...